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Abstrak
Latar belakang: Organisasi Kesehatan Sedunia (WHO) mendefinisikan Farmakovigilansi(PV) sebagai ilmu 
dan kegiatan yang berhubungan dengan deteksi, evaluasi, analisa dan pencegahan terjadinya efek samping 
yang berhubungan dengan obat. Tujuan PV adalah untuk meningkatkan pelayanan dan keamanan pasien 
yang mendapatkan obat. Indonesia telah bergabung bersama gerakan pengawasan obat internasional yang 
digagas WHO sejak tahun 1970, namun pelaksanaan kegiatan ini masih sangat minim. Peran serta tenaga 
kesehatan pada kegiatan ini juga masih sangat rendah. Survei ini bertujuan untuk menganalisis tingkat 
pengetahuan, sikap dan perilaku tenaga kesehatan (NAKES) di Indonesia terhadap PV.
Metode: Penelitian ini adalah survei menggunakan kuesioner yang disebarkan secara tertulis dalam seminar 
kesehatan dan menggunakan media daring. Kuesioner terdiri dari 6 pertanyaan/pernyataan mengenai 
pengetahuan, 6 pernyataan mengenai sikap, dan apakah NAKES yang menjumpai efek samping telah menangani 
dan melaporkan efek samping tersebut dengan baik. Jika responden menjawab benar 80 % dari total pertanyaan 
pada bagian pengetahuan dan sikap, mereka digolongkan sebagai berpengetahuan atau bersikap baik. 
Hasil: Kami menganalisis 109 dari 118 kuesioner yang dibagikan. Sebagian besar responden adalah perempuan 
(82,6%), dokter (91,7%), dan bekerja di level pelayanan primer.  Pengetahuan yang baik tentang PV ditemukan 
pada 25,7% responden, sementara sikap terhadap PV yang baik 20% responden. Hanya 4 (3,%) dari total 
responden dapat dikategorikan sebagai pelaku PV yang baik. Kami tidak menemukan hubungan signifikan 
antara tingkat pengetahuan, sikap dan faktor lain dengan praktik PV yang buruk di antara HCP di Indonesia.
Kesimpulan: Pengetahuan, sikap dan perilaku tenaga kesehatan di Indonesia tentang PV masih rendah. 
Diperlukan sosialisasi berkelanjutan mengenai PV bagi para tenaga kesehatan di berbagai level. (Health 
Science Journal of Indonesia 2016;7:59-63)
Kata kunci: farmakovigilansi, tenaga kesehatan, keselamatan pasien.
Abstract
Background: World Health Organization (WHO) defines pharmacovigilance (PV) as a science and 
activities relating to detection, assessment, understanding and prevention of adverse effect or any other drug related 
problem. It aims to enhance patient care and patient safety in drug use. Although Indonesia has joined WHO 
international drug safety monitoring program since 1970s, the implementation is not applied effectively especially 
in developing country and there are poor contribution of health care professionals (HCPs) as an agent of the 
program. In this study, we assessed current knowledge, activities and practice of PV among HCPs in Indonesia.
Methods: This is a preliminary survey using a questionnaire distributed among HCPs through health seminar 
and internet. The questionnaire consists of statement/question about knowledge(6), activities(6) and whether 
HCPs who encounter ADRs handle and report it correctly.  If the respondents gave 80 % suitable answers in 
the knowledge or attitude sections, they were categorized as having “good” knowledge or attitude. We analyzed 
whether knowledge, attitude and other characteristic had any influence on the respodents PV practice.
Results: We included 109 questionnaires from 118 distributed questionnaires. Most of the respondents were females 
(90 respondents, 82.6%), medical doctors (100 respondents, 91.7%), and were working in primary health care level. 
Good knowledge was found in 28 (25.7 %) of respondents, while good attitude towards PV were found in less than 
20 % (18) of the respondents. Only 4 (3.7 %) of total respondents did a good pharmacovigilance practice.  We found 
no significant association between level of knowledge, attitude and other factors to the poor pratice of PV. 
Conclusion: The knowledge, activities and practices of pharmacovigilance among HCPs in Indonesia 
were poor and requires a continuous socialization among HCPs in different level of care. (Health Science 
Journal of Indonesia 2016;7:59-63)
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World Health Organization (WHO) defines pharma­
covigilance as a science and activities relating to 
detection, assessment, understanding and prevention 
of adverse effect or any other drug related problem.1 
It aims to enhance patient care and patient safety 
in drug use. Although WHO has established this 
program since 1961, the implementation is not 
applied effectively especially in developing country 
and there are poor contribution of healthcare pro­
fessions as an agent of the program.1
Since 1975.  Indonesia has joined the WHO program for 
international drug monitoring. First it was introduced as 
MESO (Monitoring efek samping obat – Drug adverse 
events monitoring program) at 6 hospitals in Indonesia. 
However, Indonesia was just officially joined the WHO 
program for the International drug monitoring at 1990s.2
Pharmacovigilance activities and training in Indo­
nesia are coordinated by the National Center for 
Pharmacovigilance under the Indonesian Regulatory 
Body (Badan Pengawasan Obat dan Makanan–
BPOM). There are two ways to report adverse drug 
reactions (ADRs) in Indonesia, the first one using paper 
form (known as the ”yellow form” and via online at 
http://e­meso.pom.go.id/. The activities depend on 
voluntary report from health care professionals (HCPs) 
and obligatory reporting from the pharmaceutical 
industries. In addition, the ministry of health coordinate 
a structured PV program for three specific drugs : HIV­
AIDS, anti tuberculosis and anti­Malarial.2
Indonesia also joined the WHO­UMC collaborating 
centre for international drug monitoring. This, all report 
received by the national centre for pharmacovigilance 
were forwarded to the international centre  in Upsala, 
Sweden through the Vigimed.2,3
Until now, there is no data yet on practice of PV 
in Indonesia, especially among HCPs. Thus this 
preliminary survey aims to describe the level of 
knowledge, attitude and practice of pharmacovigilance 
among HCPs in Indonesia.
METHODS
A survey was conducted between February to November 
2015 using our self­generated questionnaire. There 
are two version of questionnaires: paper and online. 
The paper questionnaires were distributed in three 
continuing medical education (CME) programs, 
conducted at February,  March and November 2015. 
Respondents of online questionnaire were openly 
invited using social media (Facebook and Twitter) at 
early February and early March 2015.
Questionnaires development
An original questionnaire in Bahasa Indonesia were 
developed by the investigators. An independent external 
reviewer was asked to evaluate the questionnaire. A 
final draft paper version of the questionnaire was then 
tested among eight health care practitioners(testing 
respondents). After independently filled in the 
question naire, each testing respondents were asked 
whether they have any difficulty in understanding the 
questions and we noted the time needed to fill in the 
questionnaire.
The test within testing respondents showed that the 
questionnaire was easy to understand, and took in average 
10­15 minutes to  complete. Minor language changes was 
made in the final version of the ques tionnaire to enhance 
comprehension. Responses from the testing respondents 
were not included in the final analysis. Subsequently, an 
Online version of the final version of the questionnaire 
was made using Google Docs.
Type of questions
The questionnaires consists of four different 
sections. In the first section, respondents were asked 
for their demographic data and health care practice 
experiences. The second until fourth sections 
discusses the knowledge, attitude and practice of 
the health care practitioners towards adverse drug 
reactions, pharmacovigilance policies and activities. 
There are six questions on knowledge and six questions 
on attitudes. Questions on knowledge include 
knowledge on definition of ADRs, reporting procedure 
of ADRs, reason for ADRs reporting and methods to 
send ADRs reports to the regulatory authority. For 
attitudes, we asked the repondents agreement on 
different statements: whether an ADRs need to be 
reported to the regulatory authority, determination of 
ADRs causality in the reports and their agreement on 
obligatory reporting for pharmaceutical industry.
In terms of practice, respondents were asked to recall 
their experience in handling adverse drug reactions 
in the last 6 months using structured questions. In 
addition we asked whether they ever received any 
information on drug safety in the last 6 months.
Ratings and data analysis
All sections were analyzed descriptively. Scoring 
was done for sections on knowledge and attitude. 
Each correct answer on knowledge and preferable 
answers on attitude towards pharmacovigilance was 
scored “1”. Respondents who responded correctly 
or preferably for more than 80 % of the questions in 
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those section were categorized as “good”.  Good PV 
practice was defined as when a HCP encounter adverse 
event, they will treat, record the event in medical 
reports and report the event to regulatory authorities. 
Data analysis were conducted using SPSS version 20.
RESULTS
In the final analysis, we included 109 questionnaires from 
118 distributed questionnaires. Nine ques tionnaires were 
excluded from the analysis due to incomplete responses. 
Most of the respondents (87, 79.8 %) filled in the paper 
questionnaire, while the others filled in the online 
questionnaire. Most of the respondents were females (90 
respondents, 82.6%), medical doctors (100 respondents, 
91.7%),  and were working in primary health care level. 
Most of them (66, 60.6 %) had less than 30 patients 
per day and 78 % of respondents regularly prescribes 
chronic medications for their patients (Table 1).
Good pharmacovigilance knowledge was found in 28 
(25.7 %) of respondents, while good attitude towards 
PV were found in less than 20 % (18) of the respondents. 
Sixty­two respondents (56.9 %) of participants have 
encounter patients with a drug’s adverse drug events in 
the past 6 months. However, only 4 of them (3.7 % of total 
respondents, 6.4 % of HCP who ever encounter adverse 
events in their pratice) did a good pharmacovigilance 
practice.  Interestingly, all of the HCP with good PV 
practice were female medical doctors work in primary 
health care. 
Table 1. Characteristic of the respondents (n=109)
Characteristics  n (%)
Female 90 (82.6)
















Average number of patients in a day
­ Less than 10
­ 11 – 29
­ 30 – 50





Treat chronic patients with chronic medications 85 (78.0)
Have a good knowledge on pharmacovigilance 28 (25.7)
Have a good attitude towards pharmacovigilance 18 (16.5)
Ever suspected or received complaints of an 
adverse event
62 (56.9)
Conduct a good pharmacovigilance practice 4 (3.7)
The most common symptoms suspected by HCP as 
an ADRs were mild to moderate ADRs including 
skin allergic reactions,  gastrointestinal discomfort 
or oedema of the palpebra. Only one HCP reported a 
serious event of Steven Johnson. The most common 
suspected ADRs complained by their patient were 
pruritus and nausea.
Most of the HCPs that ever encounter adverse event 
in their practice (29 out of 62) treated the adverse 
event and stop the suspected drugs, without recorded 
it in the medical record or reported the event to the 
regulatory authorities. Most of the respondents said 
that they never receive any update safety information 
of a drug in last six month (77 respondents, 70.6 
%). Among respondents that had received update 
safety information of a drug, half of them (16 out 
of 32 respondents) got the information from the 
pharmaceutical industries.
In table 2, we describe the knowledge and attitudes 
items in details. More than half of the respondents 
(56 respondents, 53.3 %) of respondents answered 
the definition of pharmacovigilance correctly. Most 
of the respondents aware that they were expected 
to voluntarily report the side effect of a drug (65 
respondents, 59.6 %). Only 21 (19.3 %) of the 
respondents awares of the “yellow form” and only 
10 (9.2%) of respondents knew about PV website 
from BPOM. 
Almost all of the respondents (104 respondents, 95.4 
% of respondents agree that an adverse event should 
be reported to the BPOM. More than 95 % of the 
respondents expects a reply from the BPOM if they 
do the adverse event reporting. Interestingly, 67.9 
% (74) respondents did not agree if the requirement 
for adverse event reporting is only obligatory for 
the pharmaceutical industry and 66.1 % (72) did not 
mind if the industry contacting them to obtain more 
information on certain adverse event.
In table 3 we describe the influence of knowledge, 
attitude and other demographic factors towards 
practice of pharmacovigilance. Although being a 
female HCP and saw more than 30 patients per day 
seems to be resulted in a good pharmacovigilance 
practice, the relationship were not statistically 
significant. There are no relationship between good 
knowledge and good attitude with practice of PV 
among HCP.
Health Science Journal of IndonesiaGwangge and Akbar62
Table 2. Knowledge and attitudes of respondents towards PV (N=109)
Knowledge Attitudes
n (%) n (%)
Correct definition of ADRs 
and unintended drug effect
56 (53.3) ADRs should be reported to BPOM 104(95.4)
Voluntary ADRs reporting 65(59.6) Regulatory agency need to give 
feedback of ADRs reports
104 (95.4)
Report the ADRs to 
regulatory agency
49 (47.6) Causality of ADRs need to be 
determined before the report can be 
submitted
23 (21.1)
Reason why ADRs need to be 
reported
79 (72.5) Any HCPs who report ADRs should 
determine the causality
6 (5.5)
Aware about “Yellow form” 21 (19.3) Not only pharmaceutical industry need 
to report ADRs
74 (67.9)
Regulatory agency website 
for PV
10 (9.2) The pharmaceutical industry may 
contact the doctor for more information 
in the light of ADRs reporting
72 (66.1)
Note: ADRs =adverse events, PV = Pharmacovigilance, BPOM = Badan Pengawasan Obat dan Makanan – Indonesian regulatory agency.
Table 3. Comparison of respondents knowledge, attitude and demographic factors with their pharmacovigilance practice (n=62)
Practice of Pharmacovigilance
Good (%) Poor (%) Relative risk (95 % CI) p*
Good knowledge 1(10.0) 9(90.0) 0.95 (0.16 – 5.7) 0.46
Good attitudes 1(25.0) 3(75.0) 0.32 (0.04 – 2.4) 0.32
Female 3 (8.8) 31(91.2) 1.12 (0.62­ 2.00) 0.67
Medical doctor 4 (9.8) 37 (90.2) 0.97 (0.92 – 1.02) 0.84
Work in primary clinics 4 (10.3) 35 (89.7) 0.92 (0.84 – 1.01) 0.72
Saw more than 30 patients 
in a day
2 (9.1) 20 (90.9) 1.05(0.38 – 2.93) 0.92
Treat chronic patients with 
chronic medications
4 (10.8) 33(89.2) 0.87 (0.77 – 1.00) 0.64
* Cox­regression with a dummy time variable of 40
DISCUSSION
In this survey we found that knowledge and attitudes 
of PV among health care professionals in Indonesia 
were very low.  Thus, it is not suprisingly, the practice 
of PV among health care profesionals were also very 
poor, where less than 4 % of our respondents had a 
good PV practice.  
The low level of knowledge, attitude and practice 
found in this study was similar with findings in 
other countries.  A systematic review of studies on 
PV activities in India showed that 55.6% of HCPs 
were not aware of the existence of the national PV 
programme. In addition, 28.7% of HCPs were not 
interested in reporting ADRs and 74.5% admitted 
that they never reported any ADRs to PV centers.4⁠ 
In our survey we only found that less than one tenth of 
HCPs that ever encounter any ADRs in their practice 
reported it corectly to the regulatory authorities. This 
number is slightly low compared to HCPs in India 
where 25 % of them has made the report. However, 
the respondents in our survey show a better attitude 
towards PV reporting with more than 90 % agree that 
ADRs should be reported to the regulatory bodies, 
while in India only 67 % of HCPs were interested to 
report ADRs to the PV centres.4⁠  
The clinical symptoms recognized by our respondents 
as ADRs were usually mild skin allergic reactions 
and gastrointestinal discomfort. This should not be 
suprising as more than 75 % of our respondents work 
in primary health care level. More severe adverse 
events were found in similar studies with HCPs 
working in hospitals as their respondents.5–7⁠ 
Results from our survey has shown that although 
efforts to train HCP on PV voluntary reports had 
been conducted in the past, a low level of knowledge, 
attitude and practice of PV still found among 
Indonesian HCPs. New innovative efforts to train 
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HCPs in practice of PV need to be done continously. 
A study in the Netherlands has shown that by a 
practice based training showed a better retainer 
of PV knowledge and practice among general 
practictioners compared to lecture­based training.8
We observed that female primary­care doctors with 
more than 30 patients per day seems to perform better 
in terms of PV reporting. However, we did not find 
any statistically significance association between 
sex, work­settings, type of HCPs and number of 
patients per day with the practice of PV. Previous 
studies in various population settings had pointed 
out that in general, knowledge, attitude and practice 
of any HCPs towards PV reporting were low.9–11 
Similar low rate good PV practice were also found 
in tertiary hospital.12 Thus, education efforts on PV 
should be targeted to all type of HCPs regardless of 
their work background. 
The education efforts need also be accompanied 
with a constant reminders on the PV system itself. In 
our survey, we found that the PV practice were not 
associated with good knowledge and awareness on 
requirement for voluntary PV reporting. A similar 
study among doctors and nurses found that although 
they had good knowledge and awareness on ADRs and 
PV reporting, their practices need to be improved.13
This survey had limitations. First, we only analyzed 
data from 109 HCPs from thousands of health care 
professionals in Indonesia, thus our results might 
not be representative. Second, respondents were 
recruited via social media, thus the reason for 
non­participation and rate of response could not 
be recorded. However, our survey includes mostly 
primary care doctors, thus may give description on 
PV situation in non­hospital settings. 
Drug safety monitoring should be conducted 
continuously to evaluate the consistency of risk­
benefit ratio profile of a drug. The monitoring relays 
heavily on voluntary information collected by 
HCPs. It also needs close collaborations of all its key 
players: the regulatory bodies, ministry of health, 
HCPs, academia and pharmaceutical industries. All 
stakeholders have their own roles in PV with the 
main goal of maintaining patient safety.  
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